Record Revenue and Growth
In Q3, Inari Medical achieved record revenue of $153.4 million, representing a 21% year-over-year growth. The company raised its full-year revenue guidance and expects sustained operating profitability in the first half of 2025.
International and Emerging Therapies Expansion
Inari's international revenue reached $11.5 million, a 76.4% increase from the prior year, primarily driven by Europe. Emerging Therapies revenue was over $8 million, up 64% year-over-year.
PEERLESS Study and Market Opportunities
The upcoming PEERLESS study presentation is expected to enhance the adoption of FlowTriever. Inari sees a $150 million opportunity to convert catheter-directed thrombolytic procedures to mechanical thrombectomy.
Strong Gross Margins
Inari maintained a best-in-class gross margin of 87.1% for Q3 2024, showing sequential improvement over the previous quarter.
Advancements in New Products
The company launched its next-gen Artix system after receiving 510(k) clearance and commenced a limited market release, addressing a $600 million U.S. TAM.